New drug targets Hard-to-Treat cancers in japanese patients

NCT ID NCT05101096

Ongoing Disease control Sponsor: Gilead Sciences Source: ClinicalTrials.gov ↗

First seen Jul 10, 2026 · Last updated Jul 10, 2026

Summary

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participants receive the drug intravenously and are monitored for side effects and response.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sacituzumab govitecan (Trodelvy)
What this could lead to: If successful, this could provide a new treatment option for Japanese patients with certain advanced solid tumors that are hard to treat.
What could go wrong: This is an early-phase study, so the drug may not work as hoped or could cause significant side effects. Results may not apply to all populations.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bladder transitional cell carcinoma hormone receptor-positive breast cancer neoplasm triple-negative breast carcinoma urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR HR+/HER2- METASTATIC BREAST CANCER METASTATIC TRIPLE NEGATIVE BREAST CANCER METASTATIC UROTHELIAL CANCER

Contacts and locations

Show contact details

Locations

Aichi Cancer Center Hospital

Aichi, 464-8681, Japan
Akita University Hospital

Akita, 010-8543, Japan
Chiba Cancer

Chūōku, 260-8717, Japan
Chiba Cancer Center

Chiba, 260-8717, Japan
Hirosaki University Hospital

Aomori, 036-8563, Japan
Hiroshima University Hospital

Minamiku, 734-8551, Japan
Hyogo Cancer Center

Hyōgo, 673-8558, Japan
Hyogo College of Medicine College Hospital

Nishinomiya-shi, 663-8501, Japan
Juntendo University Hospital

Bunkyō City, 113-8431, Japan
Kagawa University Hospital

Kagawa, 761-0793, Japan
Kanagawa Cancer Center

Asahi-ku, 241-8515, Japan
Keio University Hospital

Tokyo, 1608582, Japan
Kindai University Hospital

Osaka, 577-8502, Japan
Kindai University Hospital

Osakasayama-shi, 589-8511, Japan
Kumamoto University Hospital

Kumamoto, 860-8556, Japan
Kyoto University Hospital

Kyoto, 606-8507, Japan
Nagoya University Hospital

Chūōku, 540-0006, Japan
Nara Medical University Hospital

Nara, 634-8522, Japan
National Cancer Center Hospital East

Chiba, 277-8577, Japan
National Cancer Center hospital

Tokyo, 104-0045, Japan
National Center for Global Health and Medicine

Shinjuku-ku, 162-8655, Japan
National Hospital Organization Hokkaido Cancer Center

Sapporo, 003-0804, Japan
National Hospital Organization Shikoku Cancer Center

Ehime, 791-0280, Japan
Okayama University Hospital

Okayama, 700-8558, Japan
Osaka International Cancer Institute

Chūōku, 541-8567, Japan
Osaka International Cancer Institute

Osaka, 5418567, Japan
Osaka Metropolitan University Hospital

Osaka, 545-0051, Japan
Osaka University Hospital

Osaka, 565-0871, Japan
Saitama Medical University

Saitama, 350-1298, Japan
Shikoku Cancer Center

Ehime, 791-0245, Japan
Showa University Hospital

Tokyo, 142-8555, Japan
The Cancer Institute Hospital of JFCR

Kōtō City, 135-8550, Japan
Tohoku University Hospital

Aoba-ku, 980-8574, Japan
Tokai University School of Medicine

Kanagawa, 259-1193, Japan
Tokyo Medical And Dental University, Medical Hospital

Tokyo, 113-8519, Japan
Yamaguchi University Hospital

Yamaguchi, 755-0046, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.